Earnings Releases·Nov 5, 2026, 6:56 AM ET

ANI Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total net revenues rose 27.6% year-over-year to $290.8 million, with GAAP net income increasing to $35.1 million ($1.51 per diluted share) and adjusted non-GAAP EBITDA surging 39.8% to $83.3 million.
Management raised 2026 adjusted non-GAAP EBITDA guidance to $290–$300 million and EPS guidance to $9.37–$9.71, while narrowing the total revenue range to $1,085–$1,125 million and lowering Cortrophin Gel revenue expectations to $480–$500 million.
The Rare Disease segment drove growth with a 35.8% revenue increase to $160.9 million, led by Cortrophin Gel up 36.1% to $138.7 million, though capacity constraints in the specialty pharmacy network have slowed revenue conversion.
Announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560.1 million to add the FDA-approved treatment EMCITATE to its portfolio, while simultaneously repurchasing $20.0 million of common stock year-to-date.